Priority review granted to lenalidomide for FL, MZLMarch 2, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Myeloma therapies raise cardiovascular risksMarch 1, 2019Multiple MyelomaThrombosisLymphoma & Plasma Cell Disorders
ZUMA-1 update: Axi-cel responses persist at 2 yearsFebruary 24, 2019TransplantationLymphoma & Plasma Cell Disorders
Dual-targeted CAR T shows ‘clinical signal’ in NHLFebruary 24, 2019TransplantationLymphoma & Plasma Cell Disorders
MRD negativity linked to survival in MM after auto-HCTFebruary 24, 2019TransplantationMultiple MyelomaLymphoma & Plasma Cell Disorders
Similar results for once- or twice-weekly carfilzomib in MMFebruary 23, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Regimen shows promise as salvage for classical HLFebruary 22, 2019Hodgkin LymphomaLymphoma & Plasma Cell Disorders
FDA grants priority review to polatuzumab vedotin for DLBCLFebruary 20, 2019Lymphoma & Plasma Cell Disorders
Researchers characterize new subtype of high-grade DLBCLFebruary 17, 2019Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Adding palbociclib upped responses in previously treated MCLFebruary 15, 2019Lymphoma & Plasma Cell Disorders